Imagion Biosystems Limited (ASX: IBX) (the Company) gives notice that, between 29 October 2021 and 4 November 2021 the Company issued 7,075,649 fully paid ordinary
The document “Appendix 3Y Change of Director’s Interest Notice” was lodged with ASX on 11 November 2021. Please click the review the full announcement at ASX.
The document “Application for quotation of +securities” was lodged with ASX on November 11, 2021. Please click to review the full announcement at ASX.
Imagion Biosystems Limited (ASX: IBX) (the Company) gives notice that, between 5 November 2021 and 11 November 2021 the Company issued 14,490,291 fully paid ordinary
The document “Response to ASX Price Query” was lodged with ASX on 9 November, 2021. Please click to review the full announcement at ASX.
The document “Application for quotation of +securities” was lodged with ASX on 4 November 2021. Please click to review the full announcement at ASX.
Imagion Biosystems Limited (ASX: IBX) (the Company) gives notice that, between 29 October 2021 and 4 November 2021 the Company issued 7,075,649 fully paid ordinary
Imagion Biosystems Limited (ASX: IBX) (the Company) gives notice that, between 22 October 2021 and 28 October 2021 the Company issued 5,730,814 fully paid ordinary
Q3 highlights: Sites added for MagSense® HER2 Breast Cancer Phase I Study Experienced Chief Development Officer added to Management Team Joint Development Agreement established with
In this video, Chief Development Officer Yalia Jayalakshmi, Ph.D. explains why she joined Imagion Biosystems, the urgency of the company’s mission, and the challenges ahead.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance